This study focuses on patients with locally advanced rectal cancer that has specific genetic characteristics – microsatellite unstable or mismatch repair-deficient. These terms refer to specific changes in the cancer cells that affect how DNA repairs itself. The study evaluates a treatment approach combining dostarlimab (marketed as JEMPERLI), which is given through intravenous infusion, with a short course of radiotherapy.
The main purpose of this research is to determine how effective this combination treatment is in controlling the cancer without the need for surgery. The treatment involves receiving dostarlimab infusions along with radiation therapy. After treatment, patients will be monitored to see if their cancer completely disappears, which would allow them to avoid surgery.
During the study, patients will receive dostarlimab infusions at a dose of 500 mg for up to 6 months. The effectiveness of this approach will be evaluated over a two-year period to check if the cancer remains controlled without surgery. Doctors will monitor patients’ overall health, how well the cancer responds to treatment, and whether the cancer returns after initial response.
France 
